Last reviewed · How we verify
Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry
To identify new candidate genes and proteins that are differentially expressed in responders' vs non-responders to anti-TNF alpha therapy at the several time points the investigators will use the transcriptomic and proteomic analyses. Demonstrate a link between gene expression and protein markers regarding prediction to anti-TNF alpha therapy efficacy.
Details
| Lead sponsor | Universidade Nova de Lisboa |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 69 |
| Start date | 2015-05 |
| Completion | 2018-05-28 |
Conditions
- Ankylosing Spondylitis
Interventions
- Adalimumab
Primary outcomes
- Clinical response biomarkers (Assessment of Spondyloarthritis International Society (ASAS) 20 and Ankylosing Spondylitis Disease Activity Score (ASDAS) — 14 weeks
To identify anti-TNF alpha clinical response biomarkers by microarrays and proteomics technology.
Countries
Portugal